Omalizumab for Difficult-to-Treat Dermatological Conditions: Clinical and Immunological Features from a Retrospective Real-Life Experience

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision

Jan Brożek, Philippe‐Jean Bousquet, Carlos E. Baena‐Cagnani et al. · Journal of Allergy and Clinical Immunology · 2010 · 1.8K citations · Full text

Life Sciences, Immunology, Otolaryngology +12

The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions.

Suofu Qin, James B. Rottman, Patricia N. Myers et al. · Journal of Clinical Investigation · 1998 · 1.4K citations · Full text

Life Sciences, Cell Biology, Immunology +13

The <scp>EAACI</scp>/<scp>GA</scp>²<scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

Torsten Zuberbier, Werner Aberer, Riccardo Asero et al. · Allergy · 2014 · 1.2K citations

Life Sciences, Dermatology, Immunology +14

Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

Marc Humbert, Richard Beasley, Jon G. Ayres et al. · Allergy · 2004 · 1.1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

Marcus Maurer, Karin Rosén, Hsin-Ju Hsieh et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17